Results from a pre-clinical interbody fusion study of Stryker Spine’s 3D-printed Tritanium PL Interbody Cage demonstrated statistically superior range of motion, bone in-growth profile and greater average construct stiffness vs. PEEK and titanium plasma-sprayed PEEK cages.
Specifically, use of the Tritanium cage demonstrated reductions in segmental motion and increases in construct stiffness across all three loading directions between 8- and 16-week post-implant time points, which were not seen within the PEEK and plasma-sprayed titanium-coated PEEK cage groups. Further, micro-CT and histological data demonstrated greater total bone volume within the Tritanium PL Cage at both 8 and 16 weeks vs. all other treatment groups.
Correlation from this ovine study to human clinical outcomes has not been demonstrated or established.
Tritanium PL received FDA 510(k) marketing clearance at the end of 1Q16 and debuted in the following quarter. Spine and knee are the initial markets of focus for the company’s 3D printing efforts, developed in its own dedicated 3D printing manufacturing facility.
Results from a pre-clinical interbody fusion study of Stryker Spine's 3D-printed Tritanium PL Interbody Cage demonstrated statistically superior range of motion, bone in-growth profile and greater average construct stiffness vs. PEEK and titanium plasma-sprayed PEEK cages.
Specifically, use of the Tritanium cage demonstrated reductions in...
Results from a pre-clinical interbody fusion study of Stryker Spine’s 3D-printed Tritanium PL Interbody Cage demonstrated statistically superior range of motion, bone in-growth profile and greater average construct stiffness vs. PEEK and titanium plasma-sprayed PEEK cages.
Specifically, use of the Tritanium cage demonstrated reductions in segmental motion and increases in construct stiffness across all three loading directions between 8- and 16-week post-implant time points, which were not seen within the PEEK and plasma-sprayed titanium-coated PEEK cage groups. Further, micro-CT and histological data demonstrated greater total bone volume within the Tritanium PL Cage at both 8 and 16 weeks vs. all other treatment groups.
Correlation from this ovine study to human clinical outcomes has not been demonstrated or established.
Tritanium PL received FDA 510(k) marketing clearance at the end of 1Q16 and debuted in the following quarter. Spine and knee are the initial markets of focus for the company’s 3D printing efforts, developed in its own dedicated 3D printing manufacturing facility.
Copy to clipboard 
